Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVLQ2P)

• Drug Name: Aromatic bicyclic compound 1 Drug Info
• Synonyms: PMID26394986-Compound-34
• Cross-matching ID:
  PubChem CID: 53354771
  TTD Drug ID: DMVLQ2P

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 2 (JAK-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[2]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[3]
Fedratinib	DM4ZBK6	Myelofibrosis	2A20.2	Approved	[4]
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Phase 3	[5]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[6]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Phase 3	[7]
XL019	DMJ6F5C	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[8]
CTP-543	DM3SYOK	Asthma	CA23	Phase 2	[9]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[10]

Drug(s) Targeting Proto-oncogene c-Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[11]
Bosutinib	DMTI8YE	Breast cancer	2C60-2C65	Approved	[11]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[12]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Al3818	DM3WP0N	Alveolar soft part sarcoma	2A60-2C35	Phase 3	[14]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[14]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[9]
KX-01	DMF0NA9	Actinic keratosis	EK90.0	Phase 3	[15]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[16]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 2 (JAK-2)	TTRMX3V	JAK2_HUMAN	Inhibitor	[1]
Proto-oncogene c-Src (SRC)	TT6PKBN	SRC_HUMAN	Inhibitor	[1]

References

• [1] A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
• [2] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [3] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
• [6] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [7] National Cancer Institute Drug Dictionary (drug id 609888).
• [8] Company report (Portola Pharmaceuticals)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
• [11] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [12] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [13] In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
• [17] Clinical pipeline report, company report or official report of Turning Point Therapeutics.